ReviewEuropean journal of neurology2025
Efficacy and Safety of Twelve Anti-Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Review in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Twelve Anti-Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.European journal of neurology · 2025Review
- Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments.Frontiers in aging neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo comparative evaluations of anti-dyskinetic drugs to mitigate levodopa-induced dyskinesia (LID) and OFF time have been performed; head-to-head anti-dyskinetic trials are unlikely to be funded. We sought to compare the efficacy, tolerability, and safety of 12 anti-dyskinetic drugs for peak-dose dyskinesia and OFF time through a Bayesian network meta-analysis.
methodsA network meta-analysis (NMA) was conducted for randomized controlled trials (RCTs) searched through the databases of MEDLINE, Embase, Cochrane Controlled Register of Controlled Trials from incipiency to January 2025. The main endpoints were the Unified Dyskinesia Rating Scale (UDysRS), modified Abnormal Involuntary Movement Scale, or the Unified Parkinson's Disease Rating Scale IV score for LID and the number of hours of OFF time in a standardized OFF-ON diary for OFF time reduction.
resultsTwenty-one RCTs were included in the analysis. The surface under the cumulative ranking curve (SUCRA) indicated that amantadine extended-release (ER) was associated with the largest improvement in the UDysRS (0.934), followed by amantadine immediate-release (IR) (0.680). For OFF time reduction, amantadine IR (0.902) and amantadine ER (0.833) were the two best treatments compared with foliglurax (0.526), mavoglurant (0.464) and sarizotan (0.012). Fipamezole ranked first in overall withdrawals (0.812). Amantadine ER ranked first in withdrawals due to adverse events (AEs) and the incidences of AEs (≥ 1 AEs) (0.900 and 0.887).
conclusionsAmantadine ER improved dyskinesia significantly versus amantadine IR. Both formulations of amantadine were superior as OFF time-reducing agents compared to other anti-dyskinetic drugs, whereas amantadine IR non-significantly reduced OFF time versus amantadine ER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.